Thank you. It's a very important question in terms of the generic reviews.
We have established the targets precisely so that we can monitor to see where we're falling short, as we are in generics.
We've seen a significant increase in the volume. In some cases we've seen an increase—I think in the last year a 33% increase is the number that sticks in my mind—in the number of submissions coming in. Even as we're gearing up—as I mentioned, doubling some of the capacity in some specific areas—the increases in volume mean that we have not yet reached our targets.
We're also doing a pilot, and we'll be evaluating it, to see whether we can better integrate our reviews and collaborate with other reviewers worldwide. If there is information that we can share back and forth to make sure that a broader pool of science expertise is looking at these questions, that may speed this up for all of us. We're piloting a number of methodologies in this area, and we'll be looking to see whether that gives us some ongoing process improvements.
But we acknowledge that this is an area that still requires work, and I can reassure the committee that this is why we've put these extra resources there, and have tried to build the systems and look for the process changes that would aid those resources to move more quickly.